Arvinas Reports Significant Revenue Decline in Q3 2025, Net Loss Improves

Arvinas, Inc. reported a significant decline in revenue for the third quarter of 2025, generating $41.9 million compared to $102.4 million in the same period last year. This decrease of $60.5 million was primarily attributed to a reduction in revenue from the Novartis License Agreement and the Novartis Asset Agreement, which were completed by the end of 2024. However, the company did recognize $20 million in revenue from a development milestone achieved under the Novartis License Agreement. For the nine months ending September 30, 2025, revenue increased to $253.1 million from $204.2 million, largely due to changes in cost estimates related to the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer.

Operating expenses for the third quarter also saw a notable reduction, with total operating expenses decreasing to $85.7 million from $162.7 million in the prior year. Research and development expenses fell to $64.7 million from $86.9 million, while general and administrative expenses dropped significantly to $21 million from $75.8 million. The overall net loss for the quarter was $35.1 million, an improvement from the $49.2 million loss reported in the same quarter of 2024. For the nine-month period, the net loss was $13.4 million, a substantial decrease from $153.8 million in the previous year.

Strategically, Arvinas has undergone significant organizational changes, including a workforce reduction of approximately 33% in mid-2025, aimed at streamlining operations and aligning with long-term development objectives. In September 2025, the company announced an additional 15% workforce reduction, primarily affecting roles related to the commercialization of vepdegestrant. The company is also collaborating with Pfizer to select a third party for the commercialization and further development of vepdegestrant, reflecting a shift in its commercialization strategy.

As of September 30, 2025, Arvinas reported cash, cash equivalents, and marketable securities totaling approximately $787.6 million, down from $1 billion at the end of 2024. The company anticipates that its current financial resources will be sufficient to fund operations into the second half of 2028. However, it continues to face challenges in generating revenue from product sales, as it has not yet received any revenue from commercial sales and expects to incur further operating losses in the near future. The outlook remains cautious, with the company emphasizing the need for additional funding to support ongoing clinical trials and operational costs.